PMC:7461420 / 44222-44496 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T213","span":{"begin":221,"end":229},"obj":"Body_part"}],"attributes":[{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma82751"}],"text":"143 Mpro, main protease [Color figure can be viewed at wileyonlinelibrary.com] In general, inhibitors possessing a Michael acceptor group as a warhead moiety could form an irreversible (covalent) bond with the catalytic cysteine residue in the following manner (Figure 14):"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T544","span":{"begin":114,"end":115},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T545","span":{"begin":142,"end":143},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"143 Mpro, main protease [Color figure can be viewed at wileyonlinelibrary.com] In general, inhibitors possessing a Michael acceptor group as a warhead moiety could form an irreversible (covalent) bond with the catalytic cysteine residue in the following manner (Figure 14):"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T456","span":{"begin":92,"end":102},"obj":"Chemical"},{"id":"T457","span":{"begin":124,"end":132},"obj":"Chemical"},{"id":"T458","span":{"begin":133,"end":138},"obj":"Chemical"},{"id":"T459","span":{"begin":221,"end":237},"obj":"Chemical"},{"id":"T460","span":{"begin":221,"end":229},"obj":"Chemical"}],"attributes":[{"id":"A456","pred":"chebi_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A457","pred":"chebi_id","subj":"T457","obj":"http://purl.obolibrary.org/obo/CHEBI_15339"},{"id":"A458","pred":"chebi_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A459","pred":"chebi_id","subj":"T459","obj":"http://purl.obolibrary.org/obo/CHEBI_32460"},{"id":"A460","pred":"chebi_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/CHEBI_15356"}],"text":"143 Mpro, main protease [Color figure can be viewed at wileyonlinelibrary.com] In general, inhibitors possessing a Michael acceptor group as a warhead moiety could form an irreversible (covalent) bond with the catalytic cysteine residue in the following manner (Figure 14):"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1335","span":{"begin":5,"end":9},"obj":"Gene"},{"id":"1343","span":{"begin":221,"end":229},"obj":"Chemical"}],"attributes":[{"id":"A1335","pred":"tao:has_database_id","subj":"1335","obj":"Gene:8673700"},{"id":"A1343","pred":"tao:has_database_id","subj":"1343","obj":"MESH:D003545"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"143 Mpro, main protease [Color figure can be viewed at wileyonlinelibrary.com] In general, inhibitors possessing a Michael acceptor group as a warhead moiety could form an irreversible (covalent) bond with the catalytic cysteine residue in the following manner (Figure 14):"}

{"project":"LitCovid-sentences","denotations":[{"id":"T403","span":{"begin":0,"end":274},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"143 Mpro, main protease [Color figure can be viewed at wileyonlinelibrary.com] In general, inhibitors possessing a Michael acceptor group as a warhead moiety could form an irreversible (covalent) bond with the catalytic cysteine residue in the following manner (Figure 14):"}